System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Roberto Luksch is an expert in Oncology at Fondazione IRCCS Istituto Nazionale dei Tumori (Italy). As of September 2026, ScienceLeadR ranks Roberto Luksch in the top 1% of experts worldwide for Sarcoma. Roberto Luksch has authored 264 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 3 of them ongoing. SLR score: 688 (community average: 125). How the SLR is computed.

LeadR Profile

Roberto Luksch Fondazione IRCCS Istituto Nazionale dei Tumori Italy
688 ScienceLeadR Reputation 688

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hematology - Pediatrics - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Fondazione IRCCS Istituto Nazionale dei Tumori

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 264

Citations

Citations: 8 197 1st author: 12 Last author: 21 Unique author: 0

Main journals

J Clin Oncol 39
Pediatr Blood Cancer 30
Tumori 21
Cancer 9
Eur J Cancer 8

Best Journals

J Clin Oncol 16
Lancet Oncol 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.
PMID 42561548 — sarcoma, ewing, cyclophosphamide, multiple chronic conditions, maintenance, sarcoma, vinorelbine, therapeutics		Cancer Treat Rev20260
The VIVA Regimen (Vinorelbine, Ifosfamide, Vincristine, and Actinomycin-D) for High-Risk Rhabdomyosarcoma: Feasibility and Outcomes From a Single-Institution Study.
PMID 42527384 — rhabdomyosarcoma, ifosfamide, neoplasms, drug therapy, vinorelbine, vincristine, dactinomycin, therapeutics, chemotherapy		Pediatr Blood Cancer20260
Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.
PMID 42487560 — bias, neoplasms, therapeutics, neuroblastoma		Pediatr Blood Cancer20260
Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].
PMID 42364926 — neoplasms, sarcoma, genes, rev		Crit Rev Oncol Hematol20260
Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?
PMID 42318456 — oncologists, neoplasms, sarcoma, neoplasm metastasis, molecular medicine, therapeutics, software		Front Oncol20260

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 3 4
Phase 2 3
N/A 2
Phase 1 2
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Recruiting 6
Completed 5
Active not recruiting 1
Unknown 1

By type:

Interventional 11
Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 13

Main Topics

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HR NBL2 High risk neuroblastoma study 2 0 of SIOP Europe Neuroblastoma SIOPEN Randomised international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction high dose chemotherapy and radiotherapy) for patients with high risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
2024-514917-36-00 — radiotherapy, induction chemotherapy, drug therapy, therapeutics, neuroblastoma, chemotherapy		Phase 3Recruiting2024
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma REGO INTER EWING1
2023-503322-39-00 — sarcoma, ewing, lung, pleura, drug therapy, sarcoma, neoplasm metastasis, therapeutics, chemotherapy		Phase 1Active not recruiting2023
Observational Study on Skeletal Ewing s Sarcoma
NCT04845893 — radiotherapy, sarcoma, ewing, pharmaceutical preparations, surgical procedures, operative, sarcoma, diagnosis, therapeutics		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS